Efficacy of poziotinib in HER2 exon 20 insertion NSCLC patients who received prior platinum-based and HER2 targeted therapies

被引：0

作者：

Prelaj, A. ^{[1
]}

Le, X. ^{[2
]}

Proto, C. ^{[3
]}

Baik, C. S. ^{[4
]}

Tchekmedyian, N. ^{[5
]}

Heymach, J. ^{[6
]}

Bhat, G. ^{[7
]}

Cornelissen, R. ^{[8
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Oncol Med Torac Dept, Milan, Italy

[2] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck, Houston, TX USA

[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[4] Univ Washington, Dept Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA

[5] City Hope Natl Med Ctr, Med Oncol, Comprehens Canc Ctr, Duarte, CA USA

[6] MD Anderson Canc Ctr, Thorac Oncol, Houston, TX USA

[7] Spectrum Pharmaceut, Dept Clin Sci, Irvine, CA USA

[8] Erasmus MC Univ, Pulm Med, Med Ctr, Rotterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2422

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1389P

引用

页数：1

共 50 条

[21] Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5).
Le, Xiuning
Shum, Elaine
Suga, Jennifer M.
Brahmer, Julie R.
Dooms, Christophe
Mamdani, Hirva
Nechushtan, Hovav
Riess, Jonathan W.
Spira, Alexander
Barrett, John A.
Dreiling, Lyndah K.
Socinski, Mark
CANCER RESEARCH, 2021, 81 (13)
[22] Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, Takayuki
Tanizaki, Junko
Paranal, Raymond M.
Endoh, Hideki
Lydon, Christine
Capelletti, Marzia
Repellin, Claire E.
Choi, Jihyun
Ogino, Atsuko
Calles, Antonio
Ercan, Dalia
Redig, Amanda J.
Bahcall, Magda
Oxnard, Geoffrey R.
Eck, Michael J.
Janne, Pasi A.
CANCER RESEARCH, 2017, 77 (10) : 2712 - 2721
[23] Exploring optimal targeted combination therapies with neratinib for HER2 mutated NSCLC
Kuraguchi, Mari
Taus, Luke J.
Zhou, Shan
Avogadri-Connors, Francesca
Cutler, Richard E.
Lalani, Alshad S.
Kirschmeier, Paul
Janne, Pasi A.
CANCER RESEARCH, 2018, 78 (13)
[24] HER2 protein quantification in multiple cancer indications identifies candidates for HER2 targeted therapies
Sellappan, Shankar
Schwartz, Sarit
Wertheimer, Ellen
Cecchi, Fabiola
Mamus, Steven W.
Catenacci, Daniel V. T.
Hembrough, Todd
CANCER RESEARCH, 2017, 77
[25] Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies
Chuang, Jody
Neal, Joel W.
Wakelee, Heather A.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S549 - S549
[26] Targeted therapy in NSCLC driven by HER2 insertions
Peters, Solange
Zimmermann, Stefan
TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (02) : 84 - 88
[27] Discovery of potent, selective, and orally bioavailable HER2 tyrosine kinase inhibitors targeting HER2 exon20 insertion mutants and HER2WT
Yoo, H. S.
Jang, S. Y.
Jeon, J.
Nam, H. Y.
Byun, J.
Lee, G.
Jeon, S.
Chon, H.
Kim, Y. Y.
Park, H.
An, Y. G.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S44 - S45
[28] HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract
Al-Dasooqi, Noor
Gibson, Rachel
Bowen, Joanne
Keefe, Dorothy
CURRENT DRUG TARGETS, 2009, 10 (06) : 537 - 542
[29] Efficacy and safety of poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)
Cornelissen, R.
Sun, S.
Wollner, M.
Garassino, M. C. C.
Prelaj, A.
Haura, E. B.
Piotrowska, Z.
Goldman, J. W.
Socinski, M.
Dreling, L.
Bhat, G.
Lebel, F.
Le, X.
ANNALS OF ONCOLOGY, 2021, 32 : S1324 - S1324
[30] A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
Heymach, J.
Negrao, M.
Robichaux, J.
Carter, B.
Patel, A.
Altan, M.
Gibbons, D.
Fossella, F.
Simon, G.
Lam, V.
Blumenschein, G.
Tsao, A.
Kurie, J.
Mott, F.
Jenkins, D.
Mack, D.
Feng, L.
Roeck, B.
Yang, Z.
Papadimitrakopoulou, V.
Elamin, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S323 - S324

← 1 2 3 4 5 →